- In February 2025, Thermo Fisher Scientific, Inc. announced the launch of its next-generation expression vector system, designed to enhance protein expression in mammalian cells. This system includes advanced regulatory elements and optimized vector backbones, improving expression efficiency and reducing time to market for biopharmaceutical companies developing protein-based therapeutics. The new platform also integrates with Thermo Fisher’s proprietary gene synthesis services, enabling seamless gene-to-protein workflows for faster drug development
- In November 2024, Agilent Technologies, Inc. introduced its latest suite of CRISPR-compatible expression vectors, designed to streamline genome editing and functional genomics research. These vectors feature enhanced cloning efficiencies, improved transfection rates, and robust protein production capabilities, supporting the rapid expansion of gene therapy research and personalized medicine. The new tools are expected to significantly reduce the time and cost associated with gene expression studies
- In October 2024, Promega Corporation launched its high-efficiency bacterial expression vectors, optimized for large-scale protein production in E. coli. These vectors are designed to address the growing demand for recombinant proteins in the pharmaceutical and biotechnology industries, offering rapid expression, high yields, and compatibility with downstream purification processes. The launch reflects Promega’s commitment to advancing life science research and biomanufacturing capabilities
- In September 2024, QIAGEN announced the release of its proprietary mammalian expression vectors, which incorporate next-generation promoters and enhancers for high-yield protein production. These vectors are tailored for use in therapeutic protein production, including monoclonal antibodies and vaccine antigens. The launch comes as QIAGEN continues to expand its portfolio of molecular biology tools, supporting drug discovery and development pipelines worldwide
